Table 1.
Patient baseline sociodemographic and clinical characteristics
| Characteristic | All patients (N=80) |
Currently taking TIP (n=46) |
Stopped TIP (n=34) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 34 (42.5) | 23 (50.0) | 11 (32.4) |
| Female | 46 (57.5) | 23 (50.0) | 23 (67.6) |
| Age, years | |||
| Mean (SD) | 24.4 (9.4) | 24.8 (9.7) | 23.9 (9.1) |
| Range | 10–50 | 10–50 | 10–50 |
| Race/ethnicity, n (%) | |||
| Caucasian | 76 (95.0) | 45 (97.8) | 31 (91.2) |
| Other | 4 (5.0) | 1 (2.2) | 3 (8.8) |
| Marital status,a n (%) | |||
| Single/never married | 51 (70.8) | 30 (71.4) | 21 (70.0) |
| Married/with partner | 20 (27.8) | 12 (28.6) | 8 (26.7) |
| Divorced | 1 (1.4) | 0 (0.0) | 1 (3.3) |
| Education,a n (%) | |||
| Vocational school or less | 22 (30.6) | 13 (31.0) | 9 (30.0) |
| Some college or higher | 50 (69.4) | 29 (69.0) | 21 (70.0) |
| Employment status,a n (%) | |||
| Working/full-time education | 53 (73.6) | 31 (73.8) | 22 (73.3) |
| Not working | 19 (26.4) | 11 (26.2) | 8 (26.7) |
| FEV1 % predicted | |||
| Mean (SD) | 67.1 (27.3) | 60.2 (27.6) | 76.5 (24.3) |
| Median (Q1, Q3) | 71.0 (43.0, 90.0) | 62.0 (34.0, 81.0) | 83.5 (57.0, 95.0) |
| BMI | |||
| Mean (SD) | 21.1 (3.0) | 20.9 (3.4) | 21.3 (2.5) |
| Median (Q1, Q3) | 20.6 (19.2, 22.9) | 20.0 (19.0, 22.5) | 21.3 (19.5, 22.9) |
Note:
a
Administered only to adolescent and adult patients (n=72).
Abbreviations: BMI, body mass index; FEV1, forced expiratory volume in 1 second; Q, quartile; SD, standard deviation; TIP, tobramycin inhalation powder.